AI-generated summary
The authors report a small randomized trial of 10 COVID-19 pneumonia patients comparing standard care with standard care plus four daily near-infrared photobiomodulation sessions targeting the lung. The PBMT group showed improvement on pulmonary scoring tools, and no PBMT patient required ICU admission or ventilation, while the control group had higher ICU admission and mortality. Given the very small sample and lack of blinding limits, these findings are preliminary.
- Participants
- 10
- Who or what was studied
- Patients with COVID-19 pneumonia, randomized to standard medical care or standard care plus adjunctive photobiomodulation
- Limits stated in the abstract
- The abstract describes a preliminary trial with only 10 patients, which limits the strength of any conclusion.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on dovepress.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation therapy, Photobiomodulation, Control group, Near-infrared, Wound healing, Laser. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.